Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,149.21 +3,540.82 (+5.94%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Eli Lilly and Company (LLY)
After hours:
| Previous close | 755.91 |
| Open | 743.00 |
| Bid | 740.00 x 1200 |
| Ask | 740.00 x 900 |
| Day's range | 730.34 - 745.00 |
| 52-week range | 419.80 - 800.78 |
| Volume | |
| Avg. volume | 3,117,708 |
| Market cap | 698.519B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 108.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.71%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
- PR Newswire
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
